BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OSE-279 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OSE-279\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05751798-2667@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:OSE-279: Phase 1/2 readout est. (NCT05751798)
DESCRIPTION:OSE-279\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Dose-
 finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Soli
 d Tumors or Lymphomas\nEstimated primary completion: December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ose-279#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05751798
URL:https://assetmemo.bio/drug/ose-279#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
